Guardant Health, Inc. (GH)
After hours: 04:42PM EDT
| Previous close | 110.15 |
| Open | 109.85 |
| Bid | 104.45 x 3000 |
| Ask | 115.00 x 800 |
| Day's range | 109.11 - 112.20 |
| 52-week range | 77.69 - 181.07 |
| Volume | 490,053 |
| Avg. volume | 995,898 |
| Market cap | 11.103B |
| Beta (5Y monthly) | 0.50 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Guardant Health to Report Second Quarter Financial Results on August 5, 2021
REDWOOD CITY, Calif., July 13, 2021--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2021 after market close on Thursday, August 5, 2021. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- Business Wire
Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling
REDWOOD CITY, Calif., Jun 22, 2021--Guardant Health, Inc. (Nasdaq: GH) adds two new products to its portfolio to help improve the management of patients with late-stage and metastatic cancers. The Guardant360 Response™ test represents a breakthrough as the first commercially available, blood-only, liquid biopsy test that detects changes in circulating tumor DNA (ctDNA) levels to provide oncologists an early indication of a patient’s response to treatment. The Guardant360 TissueNext™ test, the co
- Business Wire
CORRECTING and REPLACING Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity
REDWOOD CITY, Calif., Jun 19, 2021--Please replace the release dated April 30, 2021, with the following corrected version due to changes in the fifth paragraph.
